Rewriting the narrative of neurodegenerative disease
Next-generation gene editing addressing the root cause of neurodegeneration
Our Mission
We are committed to expanding the reach of genetic medicine into the brain and transforming the treatment landscape for severe neurodegenerative diseases. Evox’s exosome-based therapies are designed to deliver safer, more effective and commercially scalable treatments, drawing on a proprietary gene editor delivered using a vector technology with strong safety track record and excellent brain access.
Pipeline
We have mapped a clear path to the clinic based on target selection supported by human genetic data and functional preclinical data as well as preclinical validation of safety, enhanced potency and standardized manufacturing of our gene editor and vector.
Partnerships
Strategic partnerships are central to our mission to advance innovative medicines for patients in need. We welcome collaboration with organizations that share our commitment to addressing the root causes of genetically-driven diseases within and outside of the CNS.
Science & technology
Our ExoEdit® genetic medicine platform pairs the natural transport capabilities of exosomes with a proprietary CRISPR-based editor to enhance on-target delivery, potency and safety of genetic medicines beyond what is possible with current technologies.
Next-gen genome editing of the CNS
